Guardian Pharmacy Services, Inc.

GRDN

$40.13

+2.79%

2026-09-03 16:00:02 EDT+$1.09

Healthcare

Medical - Care Facilities

NYSE

Active Trading

Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted ...

Price Action of GRDN

$40.13

+2.79%+$1.09

High—

Low—

52W High-14.7%

Rel. vol—

Interval

Range5.3h

Volume—SMA5SMA10

—

Guardian Pharmacy Services, Inc. (NYSE: GRDN) is a prominent player in the long-term care pharmacy sector, headquartered in Atlanta, Georgia. Founded in 2004 by Fred Burke, Kendall Forbes, and David Morris, the company has grown from a small operation to one of the nation's largest LTC pharmacy providers, serving over ...Guardian Pharmacy Services, Inc. (NYSE: GRDN) is a prominent player in the long-term care pharmacy sector, headquartered in Atlanta, Georgia. Founded in 2004 by Fred Burke, Kendall Forbes, and David Morris, the company has grown from a small operation to one of the nation's largest LTC pharmacy providers, serving over 195,000 residents across diverse care settings such as assisted living, behavioral health, and group homes. The company's core purpose is to deliver compassionate, community-focused pharmacy services that enhance health outcomes and reduce healthcare costs. Guardian offers a comprehensive suite of services, including personalized clinical consultation, efficient drug distribution, and administrative support, all powered by advanced technology. Their proprietary platform, Guardian Compass, provides data analytics and insights to optimize pharmacy operations and performance. Additionally, they develop GuardianShield Programs, which are specialized safety and compliance programs tailored for long-term care facilities. Financially, Guardian has demonstrated strong growth, with fiscal 2025 Q2 revenue reaching $344.3 million, a 15% year-over-year increase. The company's financial metrics are healthy, with a gross profit margin of 21.6%, a net profit margin of 4.5%, and a strong current ratio of 1.65. The company's market capitalization stands at approximately $2.78 billion, and it boasts a low beta of 0.10, indicating low volatility. Its IPO occurred on September 26, 2024, and it trades on the New York Stock Exchange. The executive team is led by President and CEO Fred Burke, a co-founder with extensive industry experience. The company employs around 3,600 full-time staff, and its employee size is classified as 1001-2000. Guardian's commitment to innovation is evident in its R&D efforts, although R&D expenses are minimal. The company's future outlook is positive, with plans to expand its network and continue leveraging technology to improve care.ExpandCollapse

Founded

2004

Employees

3600

CEO

Fred Burke

Full Name

Guardian Pharmacy Services, Inc.

Sector

Healthcare

Industry

Medical - Care Facilities

ROE

30.80%

Market Cap

$2.54B

Current Ratio

1.65

WACC

5.43%

ROIC

23.42%

Contact Information

https://guardianpharmacy.com

404 810 0089

300 Galleria Parkway SE, Atlanta, GA 30339

Key Metrics of GRDN

Snapshot

Latest / TTM · 6 periods

Market Cap

$2.54B

ROCE

31.7%

EV / EBITDA

21.81x

-3.6% YoY

FCF Yield

3.1%

-1.2% YoY

Cash Conversion Cycle

7.5d

Current Ratio

1.65

Quick take

TTM —

Positive CCC

Financial Highlights of GRDN

Profitability trend

Latest / TTM · 6 periods

Gross Margin

21.6%

Net Margin

4.5%

P/E Ratio

38.22x

n/a

Debt / Equity

0.14

n/a

Current Ratio

1.65

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of GRDN

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.32 · Revenue $365.84M · 4 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.41 · Revenue $386.91M · 4 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $1.30 · Revenue $1.44B · 4 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.28 · Revenue $361.55M · 1 analysts

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $0.34 · Revenue $351.77M
View filing
May 6, 2026
Q1 FY2026 · Results reported
EPS $0.21 · Revenue $336.60M
View filing
Mar 11, 2026
FY2025 · Annual results
EPS $0.78 · Revenue $1.45B
View filing
Nov 10, 2025
Q3 FY2025 · Results reported
EPS $0.15 · Revenue $377.43M
View filing
Aug 11, 2025
Q2 FY2025 · Results reported
EPS $0.14 · Revenue $344.33M
View filing
May 12, 2025
Q1 FY2025 · Results reported
EPS $0.15 · Revenue $329.31M
View filing

Financial Statements of GRDN

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$1.4B	+17.9%	+4.5%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$49.2M	+156.4%	+64.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+19.5%	-2.1%	+0.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+6.1%	+219.8%	+11.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+3.4%	+147.8%	+57.4%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$80.7M	+94.1%	+2336.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+5.6%	+64.5%	+2230.9%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	18.1%	-14.5%	-14.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.38x	+30.8%	+12.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$412.7M	+28.6%	+3.9%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	0.78 vs 0.98	-20.6%	0.34 vs 0.32	+7.9%
Revenue Surprise	$1.4B vs $1.4B	+0.6%	$351.8M vs $365.8M	-3.8%

Insider Transactions of GRDN

Acquisitions (A)

Since Apr 1, 2026

Disposals (D)

Since Apr 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
May 5, 2026	COSLER STEVEN D	director	Class A Common Stock	A	4,028	—
May 5, 2026	LEWIS RANDALL J	director	Class A Common Stock	A	4,028	—
May 5, 2026	Patchett Mary Sue	director	Class A Common Stock	A	4,028	—
Apr 1, 2026	Eakins Richard	officer: Senior Vice President, Sales	Class A Common Stock	—	0	—
Apr 1, 2026	Eakins Richard	officer: Senior Vice President, Sales	Class B Common Stock	—	36,052	—

Earnings Call Transcript of GRDN

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Hello, everyone. Thank you for joining us, and welcome to Guardian Pharmacy's Second Quarter 2026 Earnings Call. [Operator Instructions] I will now hand the call over to Ashley Stockton, Investor Relations. Please go ahead. Ashley Stockton: Good afternoon. Thank you for participating in today's conference call. This is Ashley Stockton, Vice President, Investor Relations for Guardian Pharmacy Services. I'm joined on today's call by Fred Burke, President and Chief Executive Officer; David Morris, Chief Operating Officer; and Will Mudd, Chief Financial Officer. After the close today, Guardian posted its financial results for the quarter ended June 30, 2026. A copy of the press release is available on the company's Investor Relations website. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release and quarterly report on Form 10-Q as well as the specific risk factors and uncertainties discussed in our annual report on Form 10-K. We do not undertake any duty to update any forward-looking statements, which speak only as of the date they are made. On today's call, we also will use certain non-GAAP financial measures when discussing the company's financial performance and condition. You can find additional information on these non-GAAP measures and reconciliations to their most directly comparable GAAP financial measures in today's press release, which again is available on our Investor Relations website. And now I will turn it over to Fred for high-level commentary. Fred Burke: Thank you, Ashley, and good afternoon, everyone. We appreciate you joining us today to review Guardian's second quarter results. But before David and Will review the second quarter in detail, I would like to begin with some perspective on our performance through the first half of 2026 and our outlook for the remainder of the year. Guardian continues to execute well, supported by solid fundamentals across our local markets and meaningful progress against our strategic priorities, including continued geographic expansion. Through the first half of 2026, reported revenue grew 2%. Absent the IRA pricing reductions, revenue would have increased low double digits, a clearer indication of the underlying growth of the business. Importantly, we have successfully mitigated the profitability impact of the changing reimbursement environment under the IRA through disciplined execution across the business, enabling us to generate adjusted EBITDA growth of 23% during the first half of 2026 compared with the first half of 2025. Based on our year-to-date …

Leadership Team of GRDN

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Fred Burke	Chief Executive Officer, President & Director	USD 845,842	Male	1950	Active
David K. Morris	COO & Director	USD 756,707	Male	1964	Active
Kendall Forbes	Executive Officer	USD 754,737	Male	1957	Active
Douglas Towns	Senior VP, General Counsel, Senior Compliance Officer & Corporate Secretary	—	Male	—	Active
Will Mudd	Senior VP & CFO	—	Male	1979	Active
Rockford Anderson	President of Right Dose Pharmacy - Iowa	—	Male	—	Active
David Martin	Senior VP of Technology, Data & Senior Security Officer	—	Male	—	Active
Jeff Tuch	SVP of Purchasing & Pricing Analytics	—	Male	—	Active
Ashley Stockton	Head of Investor Relations & Senior Director	—	Female	—	Active
Bob Weir R.Ph	SVP of Operations & Regulatory Support	—	—	—	Active
Vicki Crabtree	Vice President of Human Resources	—	Female	—	Active

Recent News of GRDN

Business Wire2 days agoNeutral

Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired assets from Tennessee-based Nautilus Pharmacy.

Defense World6 days agoNeutral

Guardian Pharmacy Services, Inc. $GRDN Shares Purchased by Bank of America Corp DE

Bank of America Corp DE increased its position in shares of Guardian Pharmacy Services, Inc. (NYSE: GRDN) by 86.1% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 128,048 shares of the company's stock after purchasing an additional 59,245 shares during the

Business Wire8/19/2026Neutral

Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will participate in the Jefferies Healthcare Services Conference, on Tuesday, September 15, 2026. Fred Burke, President and Chief Executive Officer, will participate in a fireside chat at 2:25 p.m. Central Standard Time that same day. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation accessible through Guardian Pharmacy.

MarketBeat8/8/2026Neutral

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services NYSE: GRDN reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.

Seeking Alpha8/7/2026Neutral

Guardian Pharmacy Services, Inc. (GRDN) Q2 2026 Earnings Call Transcript

Historical Employee Count of GRDN

Current

3,600

Change

+5.88%

Minimum

3,400

Maximum

3,600

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	3,600	10-K	Mar 11, 2026	View
Dec 31, 2024	3,400	10-K	Mar 26, 2025	View

Related stocksMedical - Distribution

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Guardian Pharmacy Services, Inc.